LXEO net incomeQ2 2026-$25.87M
LXEO net income was -$25.87M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.10M a year earlier. For the full fiscal 2025 it was -$99.96M, compared with -$98.33M in fiscal 2024.
Lexeo Therapeutics Inc. (LXEO) financials
For the twelve months ended Jun 30, 2026, Lexeo Therapeutics Inc. reported -$87.27M of net income.
- Net income, TTM
- -$87.27M
- Free cash flow, TTM
- -$88.70M
- Cash
- $92.83M
- Market cap
- $257.6M
FY2022FY2025
FY2022FY2025
LXEO revenue and earnings growth
LXEO EPSQ2 2026-$0.30
LXEO diluted EPS was -$0.30 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.86.
LXEO free cash flowQ2 2026-$17.60M
LXEO free cash flow was -$17.60M in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$98.96M, compared with -$81.63M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | - | - | - | $654.0K |
| Research and development | $63.80M | $74.09M | $53.13M | $49.16M |
| Selling, general and admin | $45.46M | $31.68M | $15.38M | $12.00M |
| Operating income | -$109.26M | -$105.77M | -$68.51M | -$60.51M |
| Interest expense | $95.0K | $137.0K | $205.0K | $91.0K |
| Pre-tax income | -$99.67M | -$98.44M | -$66.39M | -$59.28M |
| Income tax | $0 | $0 | - | - |
| Net income | -$99.96M | -$98.33M | -$66.39M | -$59.28M |
| EPS, basic | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
| EPS, diluted | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
| Diluted shares | 53.6M | 31.8M | 5.4M | 1.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $63.00M | $38.27M | $124.72M | $80.59M |
| Short-term investments | - | $86.50M | - | - |
| Current assets | $188.39M | $126.12M | $124.29M | $80.05M |
| Total assets | $268.69M | $146.94M | $139.81M | $97.08M |
| Current liabilities | $16.81M | $22.85M | $17.24M | $14.35M |
| Total liabilities | $22.02M | $30.10M | $26.27M | $25.00M |
| Shareholders' equity | $246.67M | $116.84M | $113.53M | -$112.95M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$98.56M | -$81.15M | -$59.50M | -$54.56M |
| Capital expenditures | $397.0K | $481.0K | $115.0K | $672.0K |
| Free cash flow | -$98.96M | -$81.63M | -$59.61M | -$55.23M |
| Investing cash flow | -$90.25M | -$94.08M | -$165.0K | -$901.0K |
| Financing cash flow | $216.79M | $88.78M | $103.79M | $189.0K |
| Stock-based compensation | $12.13M | $12.47M | $3.04M | $1.78M |
| Depreciation and amortization | $268.0K | $304.0K | $271.0K | $120.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $19.03M | $15.70M | $16.21M | $15.70M | $14.72M | $17.17M | $18.37M | $23.42M | $16.56M | $15.74M | $8.21M | $17.25M |
| Selling, general and admin | $8.99M | $6.63M | $6.91M | $5.95M | $15.97M | $16.63M | $9.02M | $8.12M | $6.99M | $7.55M | $6.76M | $3.03M |
| Operating income | -$28.02M | -$22.33M | -$23.12M | -$21.65M | -$30.69M | -$33.80M | -$27.38M | -$31.54M | -$23.55M | -$23.29M | -$14.97M | -$20.27M |
| Interest expense | $14.0K | $17.0K | $20.0K | $22.0K | $25.0K | $28.0K | $30.0K | $35.0K | $35.0K | $37.0K | $50.0K | $52.0K |
| Pre-tax income | -$25.87M | -$20.20M | -$20.63M | -$20.28M | -$26.10M | -$32.66M | -$26.03M | -$29.49M | -$21.24M | -$21.68M | -$14.19M | -$20.11M |
| Net income | -$25.87M | -$20.20M | -$20.92M | -$20.28M | -$26.10M | -$32.66M | -$25.92M | -$29.49M | -$21.24M | -$21.68M | -$14.19M | -$20.11M |
| EPS, basic | -$0.30 | -$0.25 | - | -$0.33 | -$0.60 | -$0.99 | -$0.79 | -$0.89 | -$0.64 | -$0.77 | - | -$12.36 |
| EPS, diluted | -$0.30 | -$0.25 | - | -$0.33 | -$0.60 | -$0.99 | -$0.79 | -$0.89 | -$0.64 | -$0.77 | - | -$12.36 |
| Diluted shares | 85.6M | 81.2M | - | 61.0M | 43.6M | 33.1M | - | 33.1M | 33.0M | 28.0M | - | 1.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $92.83M | $71.77M | $63.00M | $41.00M | $38.73M | $32.16M | $38.27M | $160.27M | $178.23M | $198.31M | $124.72M | $38.70M |
| Short-term investments | - | - | - | - | - | $70.92M | $86.50M | - | - | - | - | - |
| Current assets | $217.91M | $200.86M | $188.39M | $127.79M | $140.06M | $105.27M | $126.12M | $159.46M | $177.15M | $198.09M | $124.29M | $38.87M |
| Total assets | $254.90M | $250.36M | $268.69M | $143.84M | $176.07M | $125.69M | $146.94M | $173.87M | $192.01M | $213.21M | $139.81M | $54.72M |
| Current liabilities | $15.69M | $14.19M | $16.81M | $17.27M | $31.59M | $30.82M | $22.85M | $26.82M | $18.88M | $21.63M | $17.24M | $23.04M |
| Total liabilities | $19.84M | $18.86M | $22.02M | $23.01M | $37.85M | $37.58M | $30.10M | $34.54M | $27.06M | $30.25M | $26.27M | $32.50M |
| Shareholders' equity | $235.06M | $231.50M | $246.67M | $120.83M | $138.22M | $88.11M | $116.84M | $139.33M | $164.95M | $182.95M | $113.53M | -$162.81M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.60M | -$21.14M | -$20.08M | -$29.55M | -$27.22M | -$21.72M | -$28.33M | -$17.81M | -$20.15M | -$14.87M | -$13.98M | -$13.95M |
| Capital expenditures | $7.0K | $35.0K | $0 | $289.0K | - | - | $0 | $83.0K | $213.0K | $185.0K | $73.0K | $3.0K |
| Free cash flow | -$17.60M | -$21.18M | -$20.08M | -$29.84M | - | - | -$28.33M | -$17.89M | -$20.36M | -$15.05M | -$14.05M | -$13.95M |
| Investing cash flow | $14.26M | $27.46M | -$101.69M | $35.01M | -$39.17M | $15.60M | -$93.58M | -$83.0K | -$218.0K | -$193.0K | -$73.0K | -$53.0K |
| Financing cash flow | $24.40M | $2.45M | $143.77M | $52.0K | $72.96M | $11.0K | -$97.0K | -$72.0K | $291.0K | $88.65M | $100.07M | $3.91M |
| Stock-based compensation | $5.69M | $2.75M | $2.71M | $2.65M | $3.07M | $3.70M | $3.51M | $3.79M | $2.85M | $2.33M | $804.0K | $875.0K |
| Depreciation and amortization | $74.0K | $73.0K | $73.0K | $73.0K | $62.0K | $60.0K | $75.0K | $83.0K | $77.0K | $69.0K | $77.0K | $78.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 13.89 | 14.16 | 11.21 | 7.40 | 4.43 | 3.42 | 5.52 | 5.95 | 9.38 | 9.16 | 7.21 | 1.69 |
Source: XBRL data Lexeo Therapeutics Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
LXEO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| LXEO | - | - | -$87.27M | - | $257.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
LXEO FAQ
5 questionsIs LXEO profitable?
No. Lexeo Therapeutics Inc. reported a net loss of $87.27M for the twelve months ended Jun 30, 2026.How much cash and debt does LXEO have?
Lexeo Therapeutics Inc. reported $92.83M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is LXEO free cash flow?
Lexeo Therapeutics Inc. generated -$88.70M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$88.37M less capital expenditures.When did LXEO last report financial results?
The latest statements here come from Lexeo Therapeutics Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this LXEO financial data come from?
Quantisnow builds these statements from the structured XBRL data Lexeo Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.